APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antibody Drug CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antibody Drug CDMO Service Market Analysis and Forecast 2026-2032

Report ID 17406756025 June 2026204 pages

Choose your research edition.

Industry ResearchAntibody Drug CDMO Service Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody Drug CDMO Service Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Antibody Drug CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody Drug CDMO Service Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody Drug CDMO Service Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Antibody Drug CDMO Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antibody Drug CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antibody Drug CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antibody Drug CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antibody Drug CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antibody Drug CDMO Service include Abzena, AGC Biologics, Axplora, Batavia Biosciences, ChemExpress, FUJIFILM, GTP Bioways, Halix and MYCENAX, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antibody Drug CDMO Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antibody Drug CDMO Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Antibody Drug CDMO Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody Drug CDMO Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antibody Drug CDMO Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antibody Drug CDMO Service revenue, projected growth trends, production technology, application and end-user industry.

Antibody Drug CDMO Service Segment by Company

Abzena

AGC Biologics

Axplora

Batavia Biosciences

ChemExpress

FUJIFILM

GTP Bioways

Halix

MYCENAX

WuXi Biologics

ProBio

Samsung Biologics

Sigma-Aldrich

Antibody Drug CDMO Service Segment by Type

Customized Service

Lab-based Service

Others

Antibody Drug CDMO Service Segment by Application

Antibody Drug Conjugates

Monoclonal Antibodies

Others

Antibody Drug CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Drug CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody Drug CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Drug CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antibody Drug CDMO Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antibody Drug CDMO Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody Drug CDMO Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antibody Drug CDMO Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Customized Service Major Player Table 3. Lab-based Service Major Player Table 4. Others Major Player Table 5. Global Antibody Drug CDMO Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Antibody Drug Conjugates Major Player Table 7. Monoclonal Antibodies Major Player Table 8. Others Major Player Table 9. Antibody Drug CDMO Service Industry Trends Table 10. Antibody Drug CDMO Service Industry Drivers Table 11. Antibody Drug CDMO Service Industry Opportunities and Challenges Table 12. Antibody Drug CDMO Service Industry Restraints Table 13. Global Antibody Drug CDMO Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Antibody Drug CDMO Service Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Antibody Drug CDMO Service Market Share by Region (2021-2026) Table 16. Global Antibody Drug CDMO Service Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Antibody Drug CDMO Service Market Share by Region (2027-2032) Table 18. Global Antibody Drug CDMO Service Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Antibody Drug CDMO Service Revenue Market Share by Players (2021-2026) Table 20. Global Antibody Drug CDMO Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Antibody Drug CDMO Service Key Players Headquarters & Area Served Table 22. Global Antibody Drug CDMO Service Players, Product Type & Application Table 23. Global Antibody Drug CDMO Service Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Antibody Drug CDMO Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Antibody Drug CDMO Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Antibody Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Antibody Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Antibody Drug CDMO Service Revenue Market Share by Type (2021-2026) Table 30. Global Antibody Drug CDMO Service Revenue Market Share by Type (2027-2032) Table 31. Global Antibody Drug CDMO Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Antibody Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Antibody Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Antibody Drug CDMO Service Revenue Market Share by Application (2021-2026) Table 35. Global Antibody Drug CDMO Service Revenue Market Share by Application (2027-2032) Table 36. Abzena Company Information Table 37. Abzena Business Overview Table 38. Abzena Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Abzena Antibody Drug CDMO Service Product Portfolio Table 40. Abzena Recent Development Table 41. AGC Biologics Company Information Table 42. AGC Biologics Business Overview Table 43. AGC Biologics Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. AGC Biologics Antibody Drug CDMO Service Product Portfolio Table 45. AGC Biologics Recent Development Table 46. Axplora Company Information Table 47. Axplora Business Overview Table 48. Axplora Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Axplora Antibody Drug CDMO Service Product Portfolio Table 50. Axplora Recent Development Table 51. Batavia Biosciences Company Information Table 52. Batavia Biosciences Business Overview Table 53. Batavia Biosciences Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Batavia Biosciences Antibody Drug CDMO Service Product Portfolio Table 55. Batavia Biosciences Recent Development Table 56. ChemExpress Company Information Table 57. ChemExpress Business Overview Table 58. ChemExpress Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. ChemExpress Antibody Drug CDMO Service Product Portfolio Table 60. ChemExpress Recent Development Table 61. FUJIFILM Company Information Table 62. FUJIFILM Business Overview Table 63. FUJIFILM Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. FUJIFILM Antibody Drug CDMO Service Product Portfolio Table 65. FUJIFILM Recent Development Table 66. GTP Bioways Company Information Table 67. GTP Bioways Business Overview Table 68. GTP Bioways Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. GTP Bioways Antibody Drug CDMO Service Product Portfolio Table 70. GTP Bioways Recent Development Table 71. Halix Company Information Table 72. Halix Business Overview Table 73. Halix Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Halix Antibody Drug CDMO Service Product Portfolio Table 75. Halix Recent Development Table 76. MYCENAX Company Information Table 77. MYCENAX Business Overview Table 78. MYCENAX Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. MYCENAX Antibody Drug CDMO Service Product Portfolio Table 80. MYCENAX Recent Development Table 81. WuXi Biologics Company Information Table 82. WuXi Biologics Business Overview Table 83. WuXi Biologics Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. WuXi Biologics Antibody Drug CDMO Service Product Portfolio Table 85. WuXi Biologics Recent Development Table 86. ProBio Company Information Table 87. ProBio Business Overview Table 88. ProBio Antibody Drug CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. ProBio Antibody Drug CDMO Service Product Portfolio Table 90. ProBio Recent Development Table 91. Samsung Biologics Company Information Table 92. Samsung Biologics Business Overview Table 93. Samsung Biologics Antibody Drug CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Samsung Biologics Antibody Drug CDMO Service Product Portfolio Table 95. Samsung Biologics Recent Development Table 96. Sigma-Aldrich Company Information Table 97. Sigma-Aldrich Business Overview Table 98. Sigma-Aldrich Antibody Drug CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Sigma-Aldrich Antibody Drug CDMO Service Product Portfolio Table 100. Sigma-Aldrich Recent Development Table 101. North America Antibody Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 102. North America Antibody Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 103. North America Antibody Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 104. North America Antibody Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 105. North America Antibody Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. North America Antibody Drug CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 107. North America Antibody Drug CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 108. Europe Antibody Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 109. Europe Antibody Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 110. Europe Antibody Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 111. Europe Antibody Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 112. Europe Antibody Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Europe Antibody Drug CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 114. Europe Antibody Drug CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 115. China Antibody Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 116. China Antibody Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 117. China Antibody Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 118. China Antibody Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 119. Asia Antibody Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 120. Asia Antibody Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 121. Asia Antibody Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 122. Asia Antibody Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia Antibody Drug CDMO Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Asia Antibody Drug CDMO Service Revenue by Region (US$ Million) & (2021-2026) Table 125. Asia Antibody Drug CDMO Service Revenue by Region (US$ Million) & (2027-2032) Table 126. SAMEA Antibody Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 127. SAMEA Antibody Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 128. SAMEA Antibody Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 129. SAMEA Antibody Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 130. SAMEA Antibody Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. SAMEA Antibody Drug CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 132. SAMEA Antibody Drug CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Antibody Drug CDMO Service Image Figure 2. Global Antibody Drug CDMO Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody Drug CDMO Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Customized Service Image Figure 5. Lab-based Service Image Figure 6. Others Image Figure 7. Global Antibody Drug CDMO Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Antibody Drug CDMO Service Market Size Share 2021 VS 2025 VS 2032 Figure 9. Antibody Drug Conjugates Image Figure 10. Monoclonal Antibodies Image Figure 11. Others Image Figure 12. Global Antibody Drug CDMO Service Market Size (US$ Million) & (2021-2032) Figure 13. Global Antibody Drug CDMO Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Antibody Drug CDMO Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Antibody Drug CDMO Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Antibody Drug CDMO Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Antibody Drug CDMO Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Antibody Drug CDMO Service Revenue Market Share by Type (2021-2032) Figure 20. Global Antibody Drug CDMO Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Antibody Drug CDMO Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Antibody Drug CDMO Service Revenue Market Share by Application (2021-2032) Figure 23. North America Antibody Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Antibody Drug CDMO Service Revenue Share by Type (2021-2032) Figure 25. North America Antibody Drug CDMO Service Revenue Share by Application (2021-2032) Figure 26. North America Antibody Drug CDMO Service Revenue Share by Country (2021-2032) Figure 27. United States Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Antibody Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Antibody Drug CDMO Service Revenue Share by Type (2021-2032) Figure 32. Europe Antibody Drug CDMO Service Revenue Share by Application (2021-2032) Figure 33. Europe Antibody Drug CDMO Service Revenue Share by Country (2021-2032) Figure 34. Germany Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Antibody Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Antibody Drug CDMO Service Revenue Share by Type (2021-2032) Figure 44. China Antibody Drug CDMO Service Revenue Share by Application (2021-2032) Figure 45. Asia Antibody Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Antibody Drug CDMO Service Revenue Share by Type (2021-2032) Figure 47. Asia Antibody Drug CDMO Service Revenue Share by Application (2021-2032) Figure 48. Asia Antibody Drug CDMO Service Revenue Share by Region (2021-2032) Figure 49. Japan Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Antibody Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Antibody Drug CDMO Service Revenue Share by Type (2021-2032) Figure 57. SAMEA Antibody Drug CDMO Service Revenue Share by Application (2021-2032) Figure 58. SAMEA Antibody Drug CDMO Service Revenue Share by Country (2021-2032) Figure 59. Brazil Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Antibody Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Customized Service
  • Lab-based Service
  • Others
Applications
  • Antibody Drug Conjugates
  • Monoclonal Antibodies
  • Others
Companies covered
  • Abzena
  • AGC Biologics
  • Axplora
  • Batavia Biosciences
  • ChemExpress
  • FUJIFILM
  • GTP Bioways
  • Halix
  • MYCENAX
  • WuXi Biologics
  • ProBio
  • Samsung Biologics
  • Sigma-Aldrich

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antibody Drug CDMO Service Market by Type
  3. 1.2.1 Global Antibody Drug CDMO Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Customized Service
  5. 1.2.3 Lab-based Service
  6. 1.2.4 Others
  7. 1.3 Antibody Drug CDMO Service Market by Application
  8. 1.3.1 Global Antibody Drug CDMO Service Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Antibody Drug Conjugates
  10. 1.3.3 Monoclonal Antibodies
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Antibody Drug CDMO Service Market Dynamics
  1. 2.1 Antibody Drug CDMO Service Industry Trends
  2. 2.2 Antibody Drug CDMO Service Industry Drivers
  3. 2.3 Antibody Drug CDMO Service Industry Opportunities and Challenges
  4. 2.4 Antibody Drug CDMO Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antibody Drug CDMO Service Market Perspective (2021-2032)
  2. 3.2 Global Antibody Drug CDMO Service Growth Trends by Region
  3. 3.2.1 Global Antibody Drug CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antibody Drug CDMO Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Antibody Drug CDMO Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antibody Drug CDMO Service Revenue by Players
  2. 4.1.1 Global Antibody Drug CDMO Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Antibody Drug CDMO Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antibody Drug CDMO Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antibody Drug CDMO Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antibody Drug CDMO Service Key Players Headquarters & Area Served
  7. 4.4 Global Antibody Drug CDMO Service Players, Product Type & Application
  8. 4.5 Global Antibody Drug CDMO Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antibody Drug CDMO Service Market CR5 and HHI
  11. 4.6.3 2025 Antibody Drug CDMO Service Tier 1, Tier 2, and Tier 3
5 Antibody Drug CDMO Service Market Size by Type
  1. 5.1 Global Antibody Drug CDMO Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antibody Drug CDMO Service Revenue by Type (2021-2032)
  3. 5.3 Global Antibody Drug CDMO Service Revenue Market Share by Type (2021-2032)
6 Antibody Drug CDMO Service Market Size by Application
  1. 6.1 Global Antibody Drug CDMO Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antibody Drug CDMO Service Revenue by Application (2021-2032)
  3. 6.3 Global Antibody Drug CDMO Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abzena
  2. 7.1.1 Abzena Company Information
  3. 7.1.2 Abzena Business Overview
  4. 7.1.3 Abzena Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abzena Antibody Drug CDMO Service Product Portfolio
  6. 7.1.5 Abzena Recent Developments
  7. 7.2 AGC Biologics
  8. 7.2.1 AGC Biologics Company Information
  9. 7.2.2 AGC Biologics Business Overview
  10. 7.2.3 AGC Biologics Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 AGC Biologics Antibody Drug CDMO Service Product Portfolio
  12. 7.2.5 AGC Biologics Recent Developments
  13. 7.3 Axplora
  14. 7.3.1 Axplora Company Information
  15. 7.3.2 Axplora Business Overview
  16. 7.3.3 Axplora Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Axplora Antibody Drug CDMO Service Product Portfolio
  18. 7.3.5 Axplora Recent Developments
  19. 7.4 Batavia Biosciences
  20. 7.4.1 Batavia Biosciences Company Information
  21. 7.4.2 Batavia Biosciences Business Overview
  22. 7.4.3 Batavia Biosciences Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Batavia Biosciences Antibody Drug CDMO Service Product Portfolio
  24. 7.4.5 Batavia Biosciences Recent Developments
  25. 7.5 ChemExpress
  26. 7.5.1 ChemExpress Company Information
  27. 7.5.2 ChemExpress Business Overview
  28. 7.5.3 ChemExpress Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 ChemExpress Antibody Drug CDMO Service Product Portfolio
  30. 7.5.5 ChemExpress Recent Developments
  31. 7.6 FUJIFILM
  32. 7.6.1 FUJIFILM Company Information
  33. 7.6.2 FUJIFILM Business Overview
  34. 7.6.3 FUJIFILM Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 FUJIFILM Antibody Drug CDMO Service Product Portfolio
  36. 7.6.5 FUJIFILM Recent Developments
  37. 7.7 GTP Bioways
  38. 7.7.1 GTP Bioways Company Information
  39. 7.7.2 GTP Bioways Business Overview
  40. 7.7.3 GTP Bioways Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GTP Bioways Antibody Drug CDMO Service Product Portfolio
  42. 7.7.5 GTP Bioways Recent Developments
  43. 7.8 Halix
  44. 7.8.1 Halix Company Information
  45. 7.8.2 Halix Business Overview
  46. 7.8.3 Halix Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Halix Antibody Drug CDMO Service Product Portfolio
  48. 7.8.5 Halix Recent Developments
  49. 7.9 MYCENAX
  50. 7.9.1 MYCENAX Company Information
  51. 7.9.2 MYCENAX Business Overview
  52. 7.9.3 MYCENAX Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 MYCENAX Antibody Drug CDMO Service Product Portfolio
  54. 7.9.5 MYCENAX Recent Developments
  55. 7.10 WuXi Biologics
  56. 7.10.1 WuXi Biologics Company Information
  57. 7.10.2 WuXi Biologics Business Overview
  58. 7.10.3 WuXi Biologics Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 WuXi Biologics Antibody Drug CDMO Service Product Portfolio
  60. 7.10.5 WuXi Biologics Recent Developments
  61. 7.11 ProBio
  62. 7.11.1 ProBio Company Information
  63. 7.11.2 ProBio Business Overview
  64. 7.11.3 ProBio Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 ProBio Antibody Drug CDMO Service Product Portfolio
  66. 7.11.5 ProBio Recent Developments
  67. 7.12 Samsung Biologics
  68. 7.12.1 Samsung Biologics Company Information
  69. 7.12.2 Samsung Biologics Business Overview
  70. 7.12.3 Samsung Biologics Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Samsung Biologics Antibody Drug CDMO Service Product Portfolio
  72. 7.12.5 Samsung Biologics Recent Developments
  73. 7.13 Sigma-Aldrich
  74. 7.13.1 Sigma-Aldrich Company Information
  75. 7.13.2 Sigma-Aldrich Business Overview
  76. 7.13.3 Sigma-Aldrich Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Sigma-Aldrich Antibody Drug CDMO Service Product Portfolio
  78. 7.13.5 Sigma-Aldrich Recent Developments
8 North America
  1. 8.1 North America Antibody Drug CDMO Service Revenue (2021-2032)
  2. 8.2 North America Antibody Drug CDMO Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Antibody Drug CDMO Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Antibody Drug CDMO Service Revenue by Type (2027-2032)
  5. 8.3 North America Antibody Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Antibody Drug CDMO Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Antibody Drug CDMO Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Antibody Drug CDMO Service Revenue by Application (2027-2032)
  9. 8.5 North America Antibody Drug CDMO Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Antibody Drug CDMO Service Revenue by Country
  11. 8.6.1 North America Antibody Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antibody Drug CDMO Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Antibody Drug CDMO Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Antibody Drug CDMO Service Revenue (2021-2032)
  2. 9.2 Europe Antibody Drug CDMO Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antibody Drug CDMO Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antibody Drug CDMO Service Revenue by Type (2027-2032)
  5. 9.3 Europe Antibody Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antibody Drug CDMO Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antibody Drug CDMO Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antibody Drug CDMO Service Revenue by Application (2027-2032)
  9. 9.5 Europe Antibody Drug CDMO Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antibody Drug CDMO Service Revenue by Country
  11. 9.6.1 Europe Antibody Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antibody Drug CDMO Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antibody Drug CDMO Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Antibody Drug CDMO Service Revenue (2021-2032)
  2. 10.2 China Antibody Drug CDMO Service Revenue by Type (2021-2032)
  3. 10.2.1 China Antibody Drug CDMO Service Revenue by Type (2021-2026)
  4. 10.2.2 China Antibody Drug CDMO Service Revenue by Type (2027-2032)
  5. 10.3 China Antibody Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 10.4 China Antibody Drug CDMO Service Revenue by Application (2021-2032)
  7. 10.4.1 China Antibody Drug CDMO Service Revenue by Application (2021-2026)
  8. 10.4.2 China Antibody Drug CDMO Service Revenue by Application (2027-2032)
  9. 10.5 China Antibody Drug CDMO Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antibody Drug CDMO Service Revenue (2021-2032)
  2. 11.2 Asia Antibody Drug CDMO Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antibody Drug CDMO Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antibody Drug CDMO Service Revenue by Type (2027-2032)
  5. 11.3 Asia Antibody Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antibody Drug CDMO Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antibody Drug CDMO Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antibody Drug CDMO Service Revenue by Application (2027-2032)
  9. 11.5 Asia Antibody Drug CDMO Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antibody Drug CDMO Service Revenue by Country
  11. 11.6.1 Asia Antibody Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antibody Drug CDMO Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antibody Drug CDMO Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antibody Drug CDMO Service Revenue (2021-2032)
  2. 12.2 SAMEA Antibody Drug CDMO Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antibody Drug CDMO Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antibody Drug CDMO Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antibody Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antibody Drug CDMO Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antibody Drug CDMO Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antibody Drug CDMO Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antibody Drug CDMO Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antibody Drug CDMO Service Revenue by Country
  11. 12.6.1 SAMEA Antibody Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antibody Drug CDMO Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antibody Drug CDMO Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst